Biogen Idec Creates Unprecedented Research Group to Discover ALS Treatment
Biogen Idec (NASDAQ:BIIB) has unveiled its new research consortium which includes various members of leading academic research organizations in its aim to identify possible treatments for amyotrophic...
View ArticleBiogen Posts Better-Than-Expected Q1 Profit
Reuters reported that Biogen Idec’s first quarter earnings amounted to $426.8 million up from $302.7 million in the year earlier period boosted by low taxes and excellent sales of its multiple...
View ArticleBiogen Idec’s ALPROLIX™ Therapy for Hemophilia B Granted Approval by Health...
Health Canadahas granted approval on Biogen Idec’s (NASDAQ:BIIB) ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], a long-acting hemophilia B therapy. Continue reading...
View ArticleInvesting in Alzheimer’s: A Look at Available Drug Treatments
November is National Alzheimer's Disease and Awareness Month in the United States. Here, Life Science Investing News takes a look at what the disease is and which companies are currently racing to come...
View Article
